AAAAAA
Results: 176-200/366
Authors:
SULLIVANKLOSE TH
GHANAYEM BI
BELL DA
ZHANG ZY
KAMINSKY LS
SHENFIELD GM
MINERS JO
BIRKETT DJ
GOLDSTEIN JA
Citation: Th. Sullivanklose et al., THE ROLE OF THE CYP2C9-LEU(359) ALLELIC VARIANT IN THE TOLBUTAMIDE POLYMORPHISM, Pharmacogenetics, 6(4), 1996, pp. 341-349
Authors:
JOHANSSON I
LUNDQVIST E
DAHL ML
INGELMANSUNDBERG M
Citation: I. Johansson et al., PCR-BASED GENOTYPING FOR DUPLICATED AND DELETED CYP2D6 GENES, Pharmacogenetics, 6(4), 1996, pp. 351-355
Authors:
EDEKI TI
GOLDSTEIN JA
DEMORAIS SMF
HAJILOO L
BUTLER M
CHAPDELAINE P
WILKINSON GR
Citation: Ti. Edeki et al., GENETIC-POLYMORPHISM OF S-MEPHENYTOIN 4'-HYDROXYLATION IN AFRICAN-AMERICANS, Pharmacogenetics, 6(4), 1996, pp. 357-360
POLYMORPHISM IN THE HUMAN O-6-METHYLGUANINE-DNA METHYLTRANSFERASE GENE DETECTED BY PCR-SSCP ANALYSIS
Authors:
OTSUKA M
ABE M
NAKABEPPU Y
SEKIGUCHI M
SUZUKI T
Citation: M. Otsuka et al., POLYMORPHISM IN THE HUMAN O-6-METHYLGUANINE-DNA METHYLTRANSFERASE GENE DETECTED BY PCR-SSCP ANALYSIS, Pharmacogenetics, 6(4), 1996, pp. 361-363
Authors:
EVANS DAP
SEIDEGARD J
NARAYANAN N
Citation: Dap. Evans et al., THE GSTM1 GENETIC-POLYMORPHISM IN HEALTHY SAUDI-ARABIANS AND FILIPINOS, AND SAUDI-ARABIANS WITH CORONARY ATHEROSCLEROSIS, Pharmacogenetics, 6(4), 1996, pp. 365-367
Authors:
SOMMER KM
RAMSDEN R
SIDHU J
COSTA P
OMIECINSKI CJ
Citation: Km. Sommer et al., PROMOTER REGION ANALYSIS OF THE RAT CYP2B1 AND CYP2B2 GENES, Pharmacogenetics, 6(4), 1996, pp. 369-374
Authors:
MOLVEN A
STEEN VM
Citation: A. Molven et Vm. Steen, A RETROVIRAL ELEMENT IN THE HUMAN CYP2D GENE-CLUSTER, Pharmacogenetics, 6(4), 1996, pp. 375-377
Authors:
DALY AK
BROCKMOLLER J
BROLY F
EICHELBAUM M
EVANS WE
GONZALEZ FJ
HUANG JD
IDLE JR
INGELMANSUNDBERG M
ISHIZAKI T
JACQZAIGRAIN E
MEYER UA
NEBERT DW
STEEN VM
WOLF CR
ZANGER UM
Citation: Ak. Daly et al., NOMENCLATURE FOR HUMAN CYP2D6 ALLELES, Pharmacogenetics, 6(3), 1996, pp. 193-201
Authors:
CARRIERE V
BERTHOU F
BAIRD S
BELLOC C
BEAUNE P
DEWAZIERS I
Citation: V. Carriere et al., HUMAN CYTOCHROME-P450 2E1 (CYP2E1) - FROM GENOTYPE TO PHENOTYPE, Pharmacogenetics, 6(3), 1996, pp. 203-211
Authors:
JEPPESEN U
LOFT S
POULSEN HE
BROSEN K
Citation: U. Jeppesen et al., A FLUVOXAMINE-CAFFEINE INTERACTION STUDY, Pharmacogenetics, 6(3), 1996, pp. 213-222
Authors:
COMINGS DE
ROSENTHAL RJ
LESIEUR HR
RUGLE LJ
MUHLEMAN D
CHIU C
DIETZ G
GADE R
Citation: De. Comings et al., A STUDY OF THE DOPAMINE D-2 RECEPTOR GENE IN PATHOLOGICAL GAMBLING, Pharmacogenetics, 6(3), 1996, pp. 223-234
Authors:
XIE HG
XU ZH
LUO XA
HUANG SL
ZENG FD
ZHOU HH
Citation: Hg. Xie et al., GENETIC POLYMORPHISMS OF DEBRISOQUINE AND S-MEPHENYTOIN OXIDATION METABOLISM IN CHINESE POPULATIONS - A METAANALYSIS, Pharmacogenetics, 6(3), 1996, pp. 235-238
Authors:
BENOWITZ NL
JACOB P
PEREZSTABLE E
Citation: Nl. Benowitz et al., CYP2D6 PHENOTYPE AND THE METABOLISM OF NICOTINE AND COTININE, Pharmacogenetics, 6(3), 1996, pp. 239-242
Authors:
LACHMAN HM
PAPOLOS DF
SAITO T
YU YM
SZUMLANSKI CL
WEINSHILBOUM RM
Citation: Hm. Lachman et al., HUMAN CATECHOL-O-METHYLTRANSFERASE PHARMACOGENETICS - DESCRIPTION OF A FUNCTIONAL POLYMORPHISM AND ITS POTENTIAL APPLICATION TO NEUROPSYCHIATRIC DISORDERS, Pharmacogenetics, 6(3), 1996, pp. 243-250
Authors:
OKKELS H
SIGSGAARD T
WOLF H
AUTRUP H
Citation: H. Okkels et al., GLUTATHIONE-S-TRANSFERASE-MU AS A RISK FACTOR IN BLADDER-TUMORS, Pharmacogenetics, 6(3), 1996, pp. 251-256
Authors:
CASCORBI I
BROCKMOLLER J
BAUER S
REUM T
ROOTS I
Citation: I. Cascorbi et al., NAT2-ASTERISK-12A (803A-]G) CODES FOR RAPID ARYLAMINE N-ACETYLATION IN HUMANS, Pharmacogenetics, 6(3), 1996, pp. 257-259
Authors:
CHOLERTON S
BOUSTEAD C
TABER H
ARPANAHI A
IDLE JR
Citation: S. Cholerton et al., CYP2D6 GENOTYPES IN CIGARETTE SMOKERS AND NON-TOBACCO USERS, Pharmacogenetics, 6(3), 1996, pp. 261-263
Authors:
TAKAKUBO F
KUWANO A
KONDO I
Citation: F. Takakubo et al., EVIDENCE THAT POOR METABOLIZERS OF (S)-MEPHENYTOIN COULD BE IDENTIFIED BY HAPLOTYPES OF CYP2C19 IN JAPANESE, Pharmacogenetics, 6(3), 1996, pp. 265-267
Authors:
SACHSE C
BROCKMOLLER J
BAUER S
REUM T
ROOTS I
Citation: C. Sachse et al., A RARE INSERTION OF T-226 IN EXON-1 OF CYP2D6 CAUSES A FRAMESHIFT ANDIS ASSOCIATED WITH THE POOR METABOLIZER PHENOTYPE - CYP2D6-ASTERISK-15, Pharmacogenetics, 6(3), 1996, pp. 269-272
Authors:
ROY NK
KONKLE B
WIRGIN I
Citation: Nk. Roy et al., CHARACTERIZATION OF CYP1A1 GENE REGULATORY ELEMENTS IN CANCER-PRONE ATLANTIC TOMCOD, Pharmacogenetics, 6(3), 1996, pp. 273-277
Authors:
ROSTAMIHODJEGAN A
NURMINEN S
JACKSON PR
TUCKER GT
Citation: A. Rostamihodjegan et al., CAFFEINE URINARY METABOLITE RATIOS AS MARKERS OF ENZYME-ACTIVITY - A THEORETICAL ASSESSMENT, Pharmacogenetics, 6(2), 1996, pp. 121-149
Authors:
LONDON SJ
DALY AK
COOPER J
CARPENTER CL
NAVIDI WC
DING L
IDLE JR
Citation: Sj. London et al., LUNG-CANCER RISK IN RELATION TO THE CYP2E1 RSA-I GENETIC-POLYMORPHISMAMONG AFRICAN-AMERICANS AND CAUCASIANS IN LOS-ANGELES-COUNTY, Pharmacogenetics, 6(2), 1996, pp. 151-158
Authors:
FUHR U
ROST KL
ENGELHARDT R
SACHS M
LIERMANN D
BELLOC C
BEAUNE P
JANEZIC S
GRANT D
MEYER UA
STAIB AH
Citation: U. Fuhr et al., EVALUATION OF CAFFEINE AS A TEST DRUG FOR CYPIA2, NAT2 AND CYP2E1 PHENOTYPING IN MAN BY IN-VIVO VERSUS IN-VITRO CORRELATIONS, Pharmacogenetics, 6(2), 1996, pp. 159-176
Authors:
DELOMENIE C
SICA L
GRANT DM
KRISHNAMOORTHY R
DUPRET JM
Citation: C. Delomenie et al., GENOTYPING OF THE POLYMORPHIC N-ACETYLTRANSFERASE (NAT2-ASTERISK) GENE LOCUS IN 2 NATIVE AFRICAN POPULATIONS, Pharmacogenetics, 6(2), 1996, pp. 177-185
Authors:
CHEN CL
LIU Q
RELLING MV
Citation: Cl. Chen et al., SIMULTANEOUS CHARACTERIZATION OF GLUTATHIONE S-TRANSFERSASE M1 AND T1POLYMORPHISMS BY POLYMERASE CHAIN-REACTION IN AMERICAN WHITES AND BLACKS, Pharmacogenetics, 6(2), 1996, pp. 187-191